gnckКолопроктологияKoloproktologia2073-75562686-7303Russian Association of Coloproctology10.33878/2073-7556-2019-18-3-56-70gnck-1504Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESИССЛЕДОВАНИЕ ИНГИБИРУЮЩЕГО И РАЗРУШАЮЩЕГО ДЕЙСТВИЯ ПРЕПАРАТА НАНОЧАСТИЦ СЕРЕБРА НА БИОПЛЕНКИ, СФОРМИРОВАННЫЕ КЛИНИЧЕСКИ ЗНАЧИМЫМИ МИКРООРГАНИЗМАМИTHE INHIBITORY AND DESTRUCTIVE ACTION OF THE SILVER NANOPARTICLE PREPARATION ON BIOFILMS FORMED BY CLINICALLY RELEVANT MICROORGANISMSСухинаМ. А.SukhinaM. A.antonyz@rambler.ruШелыгинЮ. А.ShelyginYu. A.ПиядинаА. Ю.PiyadinaA. Yu.ФельдманН. Б.FeldmanN. B.АнанянМ. А.AnanyanM. A.ЛуценкоС. В.LutsenkoS. V.ФроловС. А.FrolovS. A.ФГБУ «ГНЦК им. А.Н. Рыжих» Минздрава РоссииРоссияState Scientific Centre of Coloproctology of the Ministry of Healthcare of RussiaRussian FederationФГБУ «ГНЦК им. А.Н. Рыжих» Минздрава России; ФГБОУ ДПО РМАНПО Минздрава РоссииРоссияState Scientific Centre of Coloproctology of the Ministry of Healthcare of Russia; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of RussiaRussian FederationФГБУ «ГНЦК им. А.Н. Рыжих» Минздрава России; ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияState Scientific Centre of Coloproctology of the Ministry of Healthcare of Russia; Sechenov University, MoscowRussian FederationФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияSechenov University, MoscowRussian FederationЗАО «Концерн «Наноиндустрия», г. МоскваРоссияNanoindustry Concern JSCRussian FederationФГБУ «ГНЦК им. А.Н. Рыжих» Минздрава России,РоссияState Scientific Centre of Coloproctology of the Ministry of Healthcare of RussiaRussian Federation201923082019183(69)5670Copyright © Сухина М.А., Шелыгин Ю.А., Пиядина А.Ю., Фельдман Н.Б., Ананян М.А., Луценко С.В., Фролов С.А., 20192019Сухина М.А., Шелыгин Ю.А., Пиядина А.Ю., Фельдман Н.Б., Ананян М.А., Луценко С.В., Фролов С.А.Sukhina M.A., Shelygin Y.A., Piyadina A.Y., Feldman N.B., Ananyan M.A., Lutsenko S.V., Frolov S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.ruproctology.com/jour/article/view/1504

ЦЕЛЬ ИССЛЕДОВАНИЯ. Получить и исследовать активность стабилизированных арабиногалактаном наночастиц серебра в отношении клинически значимых штаммов пленкообразующих микроорганизмов. МАТЕРИАЛЫ И МЕТОДЫ. Наночастицы серебра получали методом восстановления из нитрата серебра в присутствии арабиногалактана с дополнительной стабилизацией диоктилсульфосукцинатом натрия. Форму и размеры наночастиц определяли методом просвечивающей электронной микроскопии, дзета-потенциал – методом электрофоретического рассеяния света. Исследование влияния препарата наночастиц на биопленкообразование проводили на 17 клинически значимых штаммах бактерий, изолированных из гемокультуры и клинического биоматериала послеоперационных пациентов колопроктологического стационара. РЕЗУЛЬТАТЫ. Получен препарат наночастиц серебра, характеризующихся средним диаметром 11,4 нм и дзета-потенциалом – 24 мВ. Минимальная ингибирующая концентрация препарата наночастиц в отношении планктонных культур бактерий составляла 120 мкг/мл; применение препарата в концентрации 100 мкг/мл снижало показатель КОЕ/мл на 7 порядков по сравнению с исходной культурой. Изучение влияния наночастиц серебра на процесс формирования биопленок показало, что в присутствии препарата процесс роста биопленок значительно снижался; при концентрации препарата 150 мкг/мл происходило полное подавление роста бактериальных пленок. Инкубация сформированных суточных биопленок с препаратом наночастиц серебра в диапазоне концентраций от 150 до 120 мкг/мл в течение 48 ч приводила к частичному или полному разрушению биополимерного матрикса. ЗАКЛЮЧЕНИЕ. Исследуемый препарат наночастиц серебра обладает большим потенциалом применения в терапии инфекционных заболеваний, вызванных пленкообразующими микроорганизмами.

AIM: to obtain and investigate the activity of silver nanoparticles stabilized with arabinogalactan in relation to clinically relevant strains of filmforming microorganisms. MATERIALS AND METHODS: silver nanoparticles were obtained by reduction from silver nitrate in the presence of arabinogalactan with additional stabilization with dioctyl sodium sulfosuccinate. The shape and size of the nanoparticles were determined by the method of transmission electron microscopy, the zeta potential by the method of electrophoretic light scattering. The study of the effect of the nanoparticles on biofilm formation was carried out on 17 clinically relevant strains of bacteria isolated from blood culture and the clinical biomaterial of postoperative patients. RESULTS: the silver nanoparticles with an average diameter of 11.4 nm and a zeta potential of –24 mV were obtained. The minimum inhibitory concentration of the nanoparticles in relation to planktonic form of bacteria was 120 µg/ml; the use of the drug at a concentration of 100 µg/ml reduced the amount of CFU by 7 orders of magnitude compared with the initial culture. The study of the effect of silver nanoparticles on the formation of biofilms showed that, in the presence of the drug, the growth of biofilms was significantly reduced; at a drug concentration of 150 µg/ml, the growth of bacterial films was completely suppressed. Incubation of the formed daily biofilms with the silver nanoparticles in the concentration range from 150 to 120 µg/ml for 48 h resulted in the partial or complete destruction of the biopolymer matrix. CONCLUSION: the studied preparation of silver nanoparticles has a great potential for use in the treatment of infectious diseases caused by biofilm forming microorganisms.

биопленкинаночастицы серебраантимикробная активностьклинические изолятыкатетер-ассоциированная инфекцияпослеоперационные раныbiofilmssilver nanoparticlesantimicrobial activityclinical isolatescatheter-associated infectionpostoperative woundsReferencesСухина М.А., Калашникова И.А., Кашников В.Н. и соавт. Влияние антибактериальных веществ на рост биопленки клинических изолятов. Колопроктология. 2018; № 2(64), с. 78-84.Sukhina M.A., Kalashnikova I.A., Kashnikov V.N. et al. Effect of antimicrobial agents on the biofilm growth of clinical isolates. Koloproktologia. 2018; no. 2 (64), pp. 78-84. (in Rus.)Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 2010; 8(4): 260-271.Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 2010; 8(4): 260-271.Anuradha K, Bangal P, Madhavendra SS. Macromolecular arabinogalactan polysaccharide mediated synthesis of silver nanoparticles, characterization and evaluation. Macromolecular Res. 2016; 24(2): 152-162.Anuradha K, Bangal P, Madhavendra SS. Macromolecular arabinogalactan polysaccharide mediated synthesis of silver nanoparticles, characterization and evaluation. Macromolecular Res. 2016; 24(2): 152-162.Bowler PG, Welsby S, Towers V. et al. Multidrug-resistant organisms, wounds and topical antimicrobial protection. Int. Wound J. 2012;9(4):387-396.Bowler PG, Welsby S, Towers V. et al. Multidrug-resistant organisms, wounds and topical antimicrobial protection. Int. Wound J. 2012;9(4):387-396.Bryaskova R, Pencheva D, Nikolov S. et al. Synthesis and comparative study on the antimicrobial activity of hybrid materials based on silver nanoparticles (AgNps) stabilized by polyvinylpyrrolidone (PVP). J. Chem. Biol. 2011;4(4):185-191.Bryaskova R, Pencheva D, Nikolov S. et al. Synthesis and comparative study on the antimicrobial activity of hybrid materials based on silver nanoparticles (AgNps) stabilized by polyvinylpyrrolidone (PVP). J. Chem. Biol. 2011;4(4):185-191.Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front. Microbiol. 2014; 5: 551.Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front. Microbiol. 2014; 5: 551.Chaloupka K, Malam Y, Seifalian AM. Nanosilver as a new generation of nanoproduct in biomedical applications. Trends Biotechnol. 2010;28(11):580-588.Chaloupka K, Malam Y, Seifalian AM. Nanosilver as a new generation of nanoproduct in biomedical applications. Trends Biotechnol. 2010;28(11):580-588.Chernousova S, Epple M. Silver as antibacterial agent: ion, nanoparticle, and metal. Angew. Chem. Int. Ed. 2013;52: 1636-1653.Chernousova S, Epple M. Silver as antibacterial agent: ion, nanoparticle, and metal. Angew. Chem. Int. Ed. 2013;52: 1636-1653.Choi O, Hu Z. Environ. Size dependent and reactive oxygen species related nanosilver toxicity to nitrifying bacteria. Sci. Technol. 2008; 42(12):4583-4588.Choi O, Hu Z. Environ. Size dependent and reactive oxygen species related nanosilver toxicity to nitrifying bacteria. Sci. Technol. 2008; 42(12):4583-4588.Dantes R, Mu Y, Belflower R. et al. Emerging Infections Program– Active Bacterial Core Surveillance MRSA Surveillance Investigators. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern. Med. 2013; 173(21): 1970-1978.Dantes R, Mu Y, Belflower R. et al. Emerging Infections Program– Active Bacterial Core Surveillance MRSA Surveillance Investigators. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern. Med. 2013; 173(21): 1970-1978.Gurunathan S, Han JW, Kwon DN et al. Enhanced antibacterial and anti-biofilm activities of silver nanoparticles against Gram-negative and Gram-positive bacteria. Nanoscale Res. Lett. 2014;9(1):373.Gurunathan S, Han JW, Kwon DN et al. Enhanced antibacterial and anti-biofilm activities of silver nanoparticles against Gram-negative and Gram-positive bacteria. Nanoscale Res. Lett. 2014;9(1):373.Habash MB, Park AJ, Vis EC et al. Synergy of silver nanoparticles and aztreonam against Pseudomonas aeruginosa PAO1 biofilms. Antimicrob. Agents Chemother. 2014; 58(10): 5818-5830.Habash MB, Park AJ, Vis EC et al. Synergy of silver nanoparticles and aztreonam against Pseudomonas aeruginosa PAO1 biofilms. Antimicrob. Agents Chemother. 2014; 58(10): 5818-5830.Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2004; 2(2):95-108.Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms:Jaiswal S, Bhattacharya K, McHale P et al. Dual effects of b-cyclodextrin-stabilised silver nanoparticles: enhanced biofilm inhibition and reduced cytotoxicity. J. Mater. Sci. Mater. Med. 2015;26(1): 52.from the natural environment to infectious diseases. Nat. Rev. Microbiol. 2004; 2(2):95-108.Lazar V. Quorum sensing in biofilms – how to destroy the bacterial citadels or their cohesion/power? Anaerobe. 2011;17(6):280-285.Jaiswal S, Bhattacharya K, McHale P et al. Dual effects of b-cyclodextrin-stabilised silver nanoparticles: enhanced biofilm inhibition and reduced cytotoxicity. J. Mater. Sci. Mater. Med. 2015;26(1): 52.Li WR, Xie XB, Shi QS et al. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl. Microbiol. Biotechnol. 2010; 85:1115-1122.Lazar V. Quorum sensing in biofilms – how to destroy the bacterial citadels or their cohesion/power? Anaerobe. 2011;17(6):280-285.Mohanty S, Mishra S, Jena P et al. An investigation on the antibacterial, cytotoxic, and antibiofilm efficacy of starch-stabilized silver nanoparticles. Nanomedicine. 2012;8: 916-924.Li WR, Xie XB, Shi QS et al. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl. Microbiol. Biotechnol. 2010; 85:1115-1122.Neverova NA, Levchuk AA, Ostroukhova LA et al. Distribution of extractive substances in wood of the Siberian larch (Larix sibirica Ledeb.). Russ. J. Bioorganic Chem. 2013;39 (7): 712-719.Mohanty S, Mishra S, Jena P et al. An investigation on the antibacterial, cytotoxic, and antibiofilm efficacy of starch-stabilized silver nanoparticles. Nanomedicine. 2012;8: 916-924.Palanisamy NK, Ferina N, Amirulhusni AN et al. Antibiofilm properties of chemically synthesized silver nanoparticles found against Pseudomonas aeruginosa. J. Nanobiotechnol. 2014; 12: 2.Neverova NA, Levchuk AA, Ostroukhova LA et al. Distribution of extractive substances in wood of the Siberian larch (Larix sibirica Ledeb.). Russ. J. Bioorganic Chem. 2013;39 (7): 712-719.Periasamy S, Joo HS, Duong AC et al. How Staphylococcus aureus biofilms develop their characteristic structure. Proc. Natl. Acad. Sci. USA. 2012; 109(4): 1281-1286.Palanisamy NK, Ferina N, Amirulhusni AN et al. Antibiofilm properties of chemically synthesized silver nanoparticles found against Pseudomonas aeruginosa. J. Nanobiotechnol. 2014; 12: 2.Rai MK, Deshmukh SD, Ingle AP et al. Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. J. Appl. Microbiol. 2012;112(5): 841-852.Periasamy S, Joo HS, Duong AC et al. How Staphylococcus aureus biofilms develop their characteristic structure. Proc. Natl. Acad. Sci. USA. 2012; 109(4): 1281-1286.Silver S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol. Rev. 2003; 27(2-3): 341-353.Rai MK, Deshmukh SD, Ingle AP et al. Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. J. Appl. Microbiol. 2012;112(5): 841-852.Taraszkiewicz A, Fila G, Grinholc M et al. Innovative strategies to overcome biofilm resistance. Biomed. Res. Int. 2013; p. 150653.Silver S. Bacterial silver resistance: molecular biology and uses and misuses of silver compounds. FEMS Microbiol. Rev. 2003; 27(2-3): 341-353.Walker B, Barrett S, Polasky S et al. Environment. Looming global-scale failures and missing institutions. Science. 2009; 325(5946): 1345-1346.Taraszkiewicz A, Fila G, Grinholc M et al. Innovative strategies to overcome biofilm resistance. Biomed. Res. Int. 2013; p. 150653.Wu D, Fan W, Kishen A et al. Evaluation of the antibacterial efficacy of silver nanoparticles against Enterococcus faecalis biofilm. J. Endod. 2014; 40(2):285-290.Walker B, Barrett S, Polasky S et al. Environment. Looming global-scale failures and missing institutions. Science. 2009; 325(5946): 1345-1346.Zhang XF, Liu ZG, Shen W et al. Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches. Int. J. Mol. Sci. 2016; 17(9): pii: E1534.Wu D, Fan W, Kishen A et al. Evaluation of the antibacterial efficacy of silver nanoparticles against Enterococcus faecalis biofilm. J. Endod. 2014; 40(2):285-290.Zhang XF, Liu ZG, Shen W et al. Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches. Int. J. Mol. Sci. 2016; 17(9): pii: E1534.Zhang XF, Liu ZG, Shen W et al. Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches. Int. J. Mol. Sci. 2016; 17(9): pii: E1534.

The authors declare that there are no conflicts of interest present.